United States Health

Verastem Oncology (NASDAQ:VSTM) reported updated Phase 1/2 TARGET-D 101 trial results for VS-7375, an investigational oral KRAS G12D inhibitor, across multiple KRAS G12D-mutated solid tumors.

Rhythm Pharmaceuticals (NASDAQ:RYTM) commercially launched IMCIVREE (setmelanotide) in Japan for patients with acquired hypothalamic obesity following its inclusion on the national insurance price list.

Alvotech (NASDAQ:ALVO) and Advanz Pharma submitted a regulatory application in Europe for AVT29, a proposed biosimilar referencing Eylea 8 mg, a treatment used for retinal diseases.

Pharming (NASDAQ:PHAR) presented Phase II topline results from a study evaluating leniolisib in patients with genetically identifiable primary immunodeficiencies involving immune dysregulation beyond activated PI3K delta syndrome (APDS).

UnitedHealth Group (NYSE:UNH) reported third-quarter 2026 results with consolidated revenue of $112.7 billion, earnings from operations of $6.6 billion, and a net margin of 3.6%.

Johnson & Johnson (NYSE:JNJ) reported third-quarter 2026 results with sales increasing 5.9% to $25.4 billion, supported by operational growth of 6.0% and adjusted operational growth of 6.1%.

Xponential Fitness (NYSE:XPOF) announced that its board of directors adopted a limited-duration stockholder rights plan as the company continues reviewing strategic alternatives to maximize shareholder value.

Steris (NYSE:STE) announced an agreement to acquire Xodus Medical, a Pennsylvania-based medical equipment company, in a transaction valued at $2.1 billion.

Mirum Pharmaceuticals (NASDAQ:MIRM) announced topline results from the Phase 3 EXPAND study evaluating LIVMARLI (maralixibat) in patients aged 6 months and older with ultra-rare cholestatic liver diseases, including biliary atresia.

Dot Ai (NASDAQ:DAIC) completed the acquisition of Envoy Technologies from BladeRanger through an all-stock transaction valued at approximately $65 million, using common stock and Series C Convertible Preferred Stock based on an agreed $6 reference price.

Bristol Myers Squibb (NYSE:BMY) announced topline results from the planned interim analysis of the Phase 3 ACTION-1 trial evaluating RYZ101 (225Ac-DOTATATE) in patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

First Tracks Biotherapeutics (NASDAQ:TRAX) reported Phase 1b results for ANB033, showing statistically significant changes in intestinal damage and immune-cell measurements during a gluten-challenge study in patients with celiac disease.